The effects of hyperprolactinemia on bone and fat

Area of Science:

• Endocrinology
• Bone Metabolism
• Pituitary Disorders

Background:

• Hyperprolactinemia, often caused by prolactin-secreting pituitary tumors, is linked to decreased bone mineral density.
• Bone loss in hyperprolactinemia is characterized by increased bone resorption, primarily affecting trabecular bone in the spine and hip.
• This bone loss is secondary to prolactin-induced hypogonadism in both sexes.

Purpose of the Study:

• To investigate the effects of hyperprolactinemia on bone mineral density and bone resorption.
• To determine if normalization of prolactin levels and gonadal function can restore bone mass.
• To explore the association between hyperprolactinemia, body composition, weight gain, insulin resistance, and endothelial dysfunction.

Main Methods:

• The study focuses on patients with hyperprolactinemia, analyzing bone mineral density, bone resorption markers, and gonadal function.
• Assessment of body composition, weight changes, insulin resistance, and endothelial function in hyperprolactinemic subjects.
• Comparison of bone parameters before and after normalization of prolactin levels and gonadal function.

Main Results:

• Patients with hyperprolactinemia exhibit decreased bone mineral density, with greater impact on trabecular bone (spine, hip) than cortical bone (distal radius).
• Normalization of prolactin and gonadal function increases bone density but does not fully normalize bone mass.
• Despite low bone density, hyperprolactinemic subjects do not show an increased fracture incidence.

Conclusions:

• Hyperprolactinemia leads to hypogonadism and subsequent bone loss, affecting bone density more than bone mass.
• The precise mechanisms of hyperprolactinemia-associated weight gain, insulin resistance, and endothelial dysfunction require further elucidation.
• While treatment improves bone density, the long-term implications for bone mass and fracture risk warrant continued investigation.